Physician profile
Alejandro Andreu
NPI 1215095872
$8,666.03
in general payments reported to CMS, 2019-2025
44 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $101 · 2021: $1,305 · 2022: $1,690 · 2023: $1,815 · 2024: $1,489 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,725 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,725.07 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $998.67 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $996.41 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $619.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $617.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $558.71 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $516.86 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $513.71 | 2021-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $447.69 | 2023-2025 | Gemtesa |
| Novo Nordisk INC | $359.11 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Radius Health, INC. | $318.02 | 2019-2025 | Tymlos |
| Astellas Pharma US INC | $289.08 | 2019-2025 | Myrbetriq, Veozah |
| Novartis Pharmaceuticals Corporation | $281.73 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $262.34 | 2019-2023 | |
| Abbvie INC. | $227.17 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $148.35 | 2021-2023 | Eliquis |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Andreu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.